Last reviewed: September 2018
Last updated: August  2018

Summary

Differentials

Common

  • Ascariasis
  • Strongyloidiasis
  • Schistosomiasis
  • Trichinellosis
  • Urticaria
  • Pemphigus
  • Bullous pemphigoid
  • Asthma
  • Eczema
  • Allergic rhinitis

Uncommon

  • Clonorchiasis
  • Fascioliasis
  • Fasciolopsiasis
  • Opisthorchiasis
  • Filariasis
  • Gnathostomiasis
  • Toxocariasis
  • Paragonimiasis
  • Ancylostoma caninum infestation
  • Coccidioidomycosis
  • Herpes gestationis
  • Drug hypersensitivity
  • Allergic bronchopulmonary aspergillosis
  • Eosinophilic granulomatosis with polyangiitis
  • Eosinophilic esophagitis
  • Eosinophilic gastroenteritis
  • Eosinophilic cellulitis (Wells syndrome)
  • Chronic eosinophilic leukemia
  • Other leukemias
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Nonhematologic malignancy-associated hypereosinophilia
  • Lymphocytic variant of hypereosinophilic syndrome
  • Idiopathic hypereosinophilic syndrome
  • Wiskott-Aldrich syndrome
  • Job syndrome
  • Hyperimmunoglobulin E syndrome
  • Severe combined immune deficiency due to adenosine deaminase deficiency
  • Omenn syndrome
  • immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
  • Autoimmune lymphoproliferative syndrome (ALPS)
  • Loeys-Dietz syndrome
  • Comel-Netherton syndrome
  • Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome
  • Muscular sarcocystosis
  • Cystoisospora belli (formerly Isospora belli) infection
  • Anisakiasis
  • Loiasis

Contributors

Authors VIEW ALL

Professor of Diagnostic Haematology

St Mary's Hospital Campus

Imperial College London

London

UK

Disclosures

BJB is an author of a number of references cited in this topic.

Consultant Haematologist

Department of Haematology

St George's University Hospitals NHS Foundation Trust

London

UK

Disclosures

JU is on Bayer, Vifor Pharma and Octapharma scientific advisory boards; Bayer, Octapharma, Shire, Vifor Pharma and Daiichi-Sankyo speaker bureaus; is involved in clinical trials associated with Portola, Bayer, Boehringer-Ingelheim and Daiichi-Sankyo; and has received travel support from Bayer.

Peer reviewers VIEW ALL

Professor of Medicine

Department of Internal Medicine

Division of Immunology/Allergy Section

University of Cincinnati

Cincinnati

OH

Disclosures

JB is the editor of the Joint Task Force Practice Parameters on Urticaria.

Associate Professor

Department of Molecular and Developmental Genetics

Katholieke Universiteit Leuven

Leuven

Belgium

Disclosures

JC is an author of a reference cited in this topic.

Use of this content is subject to our disclaimer